Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Accenture
Johnson and Johnson
UBS
Cerilliant
Harvard Business School
Colorcon
Boehringer Ingelheim
Fish and Richardson
Cantor Fitzgerald
Citi

Generated: February 20, 2018

DrugPatentWatch Database Preview

ADCIRCA Drug Profile

« Back to Dashboard

Which patents cover Adcirca, and what generic alternatives are available?

Adcirca is a drug marketed by Eli Lilly Co and is included in one NDA. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty-four patent family members in fifty-two countries.

The generic ingredient in ADCIRCA is tadalafil. There are twenty-three drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the tadalafil profile page.
Summary for ADCIRCA
Drug patent expirations by year for ADCIRCA
Pharmacology for ADCIRCA
Medical Subject Heading (MeSH) Categories for ADCIRCA

US Patents and Regulatory Information for ADCIRCA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ADCIRCA
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Tablets 20 mg ➤ Subscribe 10/15/2009

Non-Orange Book US Patents for ADCIRCA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors ➤ Try a Free Trial
6,140,329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence ➤ Try a Free Trial
6,841,167 .beta.-carboline pharmaceutical compositions ➤ Try a Free Trial
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use ➤ Try a Free Trial
6,608,065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction ➤ Try a Free Trial
6,784,179 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
6,369,059 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
6,025,494 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
6,127,542 Tetracyclic derivatives, process of preparation and use ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents for ADCIRCA

Supplementary Protection Certificates for ADCIRCA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2003 00008 Denmark ➤ Try a Free Trial
2003001,C0740668 Lithuania ➤ Try a Free Trial PRODUCT NAME: TADALAFILUM ((6R,12AR)-2,3,6,7,12,12A-HEKSAHIDRO-2-METIL-6-(3,4-METILENDIOKSIFENIL)-PIRAZINO(2',1':6,1)PIRIDO(3,4-B)INDOL-1,4-DIONAS); REGISTRATION NO/DATE: 03/8034/3, 03/8035/3 20030328
2016 00024 Denmark ➤ Try a Free Trial PRODUCT NAME: AMBRISENTAN USED IN COMBINATION TREATMENT WITH TADALAFIL; REG. NO/DATE: EU/1/08/451 (001-004) 20151125
C/GB03/007 United Kingdom ➤ Try a Free Trial PRODUCT NAME: TADALAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS, ESTERS AND SOLVATES THEREOF.; REGISTERED: UK EU/1/02/237/001-004 20021114
017 Luxembourg ➤ Try a Free Trial
C0017 France ➤ Try a Free Trial PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112
0124 Netherlands ➤ Try a Free Trial 300124, 20150119, EXPIRES: 20171111
081 Luxembourg ➤ Try a Free Trial PRODUCT NAME: AMBRISENTAN UTILISE EN TRAITEMENT COMBINE AVEC TADALAFIL; FRIST REGISTRATION: 20151125
C004/2003 Ireland ➤ Try a Free Trial SPC004/2003, 20040610, EXPIRES: 20171111
2016000039 Germany ➤ Try a Free Trial PRODUCT NAME: AMBRISENTAN IN VERWENDUNG IN DER KOMBINATIONSTHERAPIE MIT TADALAFIL; REGISTRATION NO/DATE: EU/1/08/451 20151120
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Merck
Fish and Richardson
Queensland Health
Express Scripts
Daiichi Sankyo
Medtronic
Baxter
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot